胺碘酮长疗程个体化治疗室性心律失常的临床疗效和安全性  

Efficacy and Safety of Amiodarone in the Treatment of Ventricular Arrythmias.

作　　者：赵长林[1] 陈璘[1] 刘金来[1] 关健强[1] 

机构地区：[1]中山医科大学附属第三医院心内科,广东广州510630

出　　处：《中国心脏起搏与心电生理杂志》2001年第5期313-314,共2页Chinese Journal of Cardiac Pacing and Electrophysiology

摘　　要：为探讨胺碘酮长疗程个体化治疗室性心律失常 (VA)的临床疗效和安全性 ,31例室性心律失常 (VA)患者给予胺碘酮个体化治疗 ,疗程 1年以上 ,观察治疗前和治疗后 1年患者室性心律失常的有效控制率、QT间期变化以及不良反应。结果 :31例患者胺碘酮的维持量为 15 5± 37mg/天 ,比推荐的用量 (2 0 0～ 40 0mg/天 )要小 ,而胺碘酮治疗室性心律失常 (VA)的有效率仍高达 90 .3% ;QT间期轻度延长 (396± 5 1msvs 438± 5 3ms ,P <0 .0 5 )。不良反应方面 ,有一例患者出现一过性FT3、FT4 升高 ;未出现扭转型室速和室颤发作 ;无肺毒性和肝肾损害等副作用。不良反应也比文献报道的非个体化治疗方案要少 (3 .2 %vs 5 %～ 15 % )。结论 :胺碘酮长疗程个体化治疗室性心律失常(VA)的临床疗效确切 ,维持用量较小 ,相关的不良反应也减少。To evaluate the efficacy and safety of Amiodarone in the treatment of the patients with ventricular arrythmia(VA),thirty one patients with VA were treated with amiodarone for more than one year individually.A low loading dose of amiodarone was given for ten days.The subsequent dose was maintained for more than one year individually.Results:90.3% of the patients with VA was controlled.One patient developed hyperthyroidism and recovered after stopping the treatment.There were no injury of lungs,liver and kidneys.NO other side effects of amiodarone were observed.Conclusion:Amiodarone is an effective and safe drug for the treatment of the patients with ventricular arrythmia(VA).

关 键 词：室性心律失常 胺碘酮 抗心律失常药 疗效 安全性 

分 类 号：R972.2[医药卫生—药品] R541.7[医药卫生—药学]